Publications

La liste ci-dessous comprend quelques publications, communications orales et affiches en lien avec la pharmacométrie clinique publiées ou présentées par les membres de l'équipe du Programme provincial de dosage des médicaments antirétroviraux. 

Publications

  • Sheehan N et collaborateurs. Ministère de la santé et des services sociaux. La pharmacométrie clinique des antirétroviraux et l’individualisation de la thérapie antirétrovirale chez les adultes et les enfants vivant avec le VIH - Guide pour les professionnels de la santé du Québec. La Direction des communications du ministère de la Santé et des Services sociaux. (lien)
  • Letarte N, Lavoie A, Sheehan N, Hurlimann T, Robb L, Lambert JP, de Denus S.  La pharmacothérapie personnalisée et la pharmacogénétique.  Pharmactuel 2013;46(4):258-68. (lien)
  • Fournier C, Higgins N, Thomas R, Baril JG, Thibeault D, Lalonde R, Sheehan NL.  Neglible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. Ther Drug Monit 2013;35(2):264-9. (PMID: 23503454)
  • Sheehan NL, van Heeswijk RPG, Foster BC, Akhtar H, Singhal N, Séguin I, et al.  The effect of beta-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients. Molecules 2012; 17:688-702. (PMID: 22241465)
  • Higgins N, Tseng A, Sheehan N, la Porte C.  Antiretroviral Therapeutic Drug Monitoring in Canada: Current Status and Recommendations for Clinical Practice. Can J Hosp Pharm 2009; 62(6): 500-9. (PMID: 22478939)
  • Sheehan NL. La pharmacocinétique clinique des antirétroviraux: de la théorie à la pratique.  Pharmactuel 2005;38(5):282-7. http://www.pharmactuel.com/sommaires/200505ve.pdf
  • Sheehan N.  Le suivi thérapeutique des antirétroviraux: théories et controverses.  Pharmactuel 2004; 37(1):21-34.  http://www.pharmactuel.com/sommaires/200401pt.pdf

Communications orales dans des congrès nationaux ou internationaux

  • Sheehan NL, Lamarre V, Soudeyns H, Higgins NM, Lapointe N.  Dose adjustments of efavirenz (EFV) based on therapeutic drug monitoring (TDM) is safe and maintains virologic suppression in HIV-infected children and adolescents.  19th Annual Canadian Conference on HIV/AIDS Research.  Saskatoon, Canada, 13 au 16 mai, 2010.
  • Higgins NM, Lapointe N, Gauthier J,  Lalonde RG, Sheehan NL. Retrospective Evaluation of Efavirenz Concentrations in Pediatric Patients in an Antiretroviral Therapeutic Drug Monitoring (TDM) Program.  Abrégé #8. 9th International Workshop on Clinical Pharmacology of HIV Therapy, Nouvelles Orléans, USA, 7 au 10 avril, 2008.
  • Higgins NM, Lalonde RG, Gibbs B, Colantonio D, Gilfix B, Boulerice A, Courchesne M, Baril JG, Blank D, Sheehan NL.  Québec Provincial Program for Antiretroviral Therapeutic Drug Monitoring.  16th Annual Canadian Conference on HIV/AIDS Research, Toronto, Canada; 26 au 29 avril, 2007.
  • Sheehan NL, Higgins NM, Boulerice A, Lalonde RG.  Evaluation of the Use of Genotypic Inhibitory Quotients in an Antiretroviral Therapeutic Drug Monitoring program [Abrégé 76].  8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hongrie, 16 au 18 avril, 2007.
  • Sheehan NL, Higgins NM, Gibbs B, Colantonio D, Gilfix B, Courchesne M, Grignon B, Baril JG, Blank D, Lalonde RG. Programme québécois de pharmacométrie clinique des antirétroviraux [Abrégé 131].   4e Conférence Francophone VIH/SIDA, Paris, France; 29 au 31 mars, 2007.
  • Lam S, Delisle MS, Labbé L, Smith GHR, la Porte CJL, Burger DM, Lalonde R, Sheehan NL.  Genotypic inhibitory quotient as best pharmacokinetic / pharmacodynamic predictor of virologic response to a lopinavir / saquinavir dual ritonavir boosted regimen in patients with multiresistant HIV-1 [Abrégé 81]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbonne, Portugal; 20 au 22 avril, 2006.  

Affiches

  • Raiyani D, Sheehan NL, Wong AYJ, Wong D, Kovacs C, Tseng A. Fluctuations in antiretroviral concentrations during acute hepatitis C: a case report. CSHP Professional Practice Conferences, Toronto, Canada, Jan 30-Feb 3, 2016.
  • Ricard F, Wong AYJ, Lebouché B, Therrien R, Lachance MJ, Munoz M, Thibeault D, Sheehan NL. Low darunavir concentrations in patients receiving Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) and darunavir once daily [Poster 50]. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy,Washington DC, May 26-28, 2015.
  • Bilirubin as a surrogate marker for atazanavir
    plasma concentrations in a paediatric population
    Wong AYJ, Dayneka N, Brophy JC, Bowes J, la Porte CJ, Samson L. Bilirubin as a surrogate marker for atazanavir plasma concentrations in a paediatric population. 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, The Netherlands, 22-24 April 2013.
  • Sheehan NL, Baril JG, Gauthier J, Higgins NM, Therrien R, Labbé L, et al.  Determination of specific indications for antiretroviral therapeutic drug monitoring using an evdience-based approach - the Québec TDM guidelines [Affiche 43].  13th International Workshop on Clinical Pharmacology of HIV Therapy.  Barcelone, Espagne, 16 au 18 avril 2012.
  • Fournier C, Higgins N, Thomas R, Baril JG, Thibeault D, Lalonde R,  Sheehan N.  Retrospective analysis of atazanavir therapeutic drug  monitoring:  is boosting with ritonavir necessary if used with tenofovir? [Affiche 41].  12th International Workshop  on Clinical Pharmacology of HIV Therapy.  Miami, USA, 13 au 15 avril, 2011. 
  • Sheehan NL, Lamarre V, Soudeyns H, Higgins NM, Lapointe N.  Dose adjustments of efavirenz based on therapeutic drug monitoring maintain virologic suppression in HIV-infected children and adolescents  [Affiche 13].    11th International Workshop on Clinical Pharmacology of  HIV Therapy, Sorrento, Italie, 7 au 9 avril, 2010.
  • Sheehan NL, la Porte C, Slayter K, Zhang G, Lalonde RG, Haase D, van Heeswijk RPG, Labbé L.  The Effects of Aging on the Pharmacokinetics of Nelfinavir and M8 in HIV-1-Infected Individuals. [Affiche 52].   10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, Pays-Bas, 15 au 17 avril, 2009.
  • Gauthier J, Boucher M, Higgins N, Moreau J, Yang H, Sheehan NL. Therapeutic drug monitoring of lopinavir/ritonavir (tablet formulation) in pregnancy [Affiche 49].  10th International Workhop on Clinical Pharmacology of HIV Therapy. Amsterdam, Pays-Bas, 15 au 17 avril, 2009.
  • Tang I, Orng B, Benyayer G, Fortier S, Perreault S, Labbé L, Higgins NM, Lalonde RG, Sheehan NL.  Evaluation of physician satisfaction with the Québec provincial antiretroviral therapeutic drug monitoring program [Affiche 55].  9th International Workshop on Clinical Pharmacology of HIV Therapy, Nouvelles Orléans, USA,  7 au 9 avril, 2008.
  • Orng B, Fortier S, Benyayer G, Tang I, Labbé L, Perreault S, Higgins NM, Lalonde RG, Sheehan NL.  Physician adherence to the pharmacological advice in an antiretroviral therapeutic drug monitoring program [Affiche 56].   9th International Workshop on Clinical Pharmacology of HIV Therapy, Nouvelles Orléans, USA, 7 au 9 avril, 2008.
  • Sheehan NL, Higgins NM, Boulerice A, Lalonde RG.  Evaluation of the Use of Genotypic Inhibitory Quotients in an Antiretroviral Therapeutic Drug Monitoring program [Affiche 76].  8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hongrie, 16 au 18 avril, 2007.
  • Lam S, Delisle MS, Labbé L, Smith GHR, la Porte CJL, Burger DM, Lalonde R, Sheehan NL.  Genotypic inhibitory quotient as best pharmacokinetic / pharmacodynamic predictor of virologic response to a lopinavir / saquinavir dual ritonavir boosted regimen in patients with multiresistant HIV-1 [Affiche 81]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbonne, Portugal; 20 au 22 avril, 2006. 
  • Sheehan NL, Bourbeau M, Foster BC, Séguin I, Akhtar H, Singhal N, Boulassel MR, DelBalso LD, Lalonde RG, van Heeswijk R, Cameron DW.  The effect of beta-carotene on the steady-state pharmacokinetics of nelfinavir and its M8 metabolite [Affiche 2.20].  6th International Workshop on Clinical Pharmacology of HIV Therapy, Québec, Canada; 28 au 30 avril, 2005.